Dr. Pietrantonio on the Design and Rationale Behind a Nomogram to Predict Survival Rates in CRC
Filippo Pietrantonio, MD, Department of Medical Oncology, Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan Fondazione IRCCS Istituto Nazionale dei Tumori, discusses a nomogram that can predict 12-week survival rates for patients with colorectal cancer.
Filippo Pietrantonio, MD, Department of Medical Oncology, Medical Oncology Unit, Milan Fondazione IRCCS Istituto Nazionale dei Tumori, discusses a nomogram that can predict 12-week survival rates for patients with colorectal cancer (CRC).
The nomogram can be utilized to identify patients with CRC who are at higher risk for death within 12 weeks, explains Pietrantonio. It can also be used as a prognostic method for patient selection, as some of these high-risk patients are enrolled on clinical trials.
Pietrantonio stresses the importance of identifying the correct patients that are able to receive further treatments, given that such stratification is currently done mostly through clinical selection due to a lack of reliability with biomarkers in this space.
FDA Places Clinical Hold on Phase 1 Trial of XMT-2056 in HER2-expressing Solid Tumors
